Manufacturing time and cost create two of the biggest challenges to making cell therapies available to more patients. Scientists at San Diego-based Artiva Biotherapeutics hope to change that with cancer and autoimmune therapies based on natural killer (NK) cells from donors—allogeneic—that are not genetically modified.
Read the article here.
Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots discusses: Immune reset in oncology has been observed with approved autologous CAR-T products. A study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Artiva’s AlloNK, an allogeneic,...
Chris Horan, Artiva’s Chief Technical Operations Officer, talks with BioProcess Insider about why decreased risk and inexpensive manufacturing might give allogeneic natural killer (NK) cell therapies the edge over chimeric antigen receptors (CAR)-T therapies. Read the article here.
Fred Aslan describes what the funds will enable Artiva to do in the clinic, and why he believes the company’s non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Watch the interview here.